Skip to main content
. 2021 Mar 25;143(13):4979–4992. doi: 10.1021/jacs.0c10644

Table 2. IC50 (Rounded) and Selectivity of Ibrutinib Derivatives against Selected Ibrutinib Kinase Off-Targets.

  BTK BLK
BMX
EGFR
ERBB2
ITK
compound IC50 (nM) IC50 (nM) BLK/BTK IC50 (nM) BMX/BTK IC50 (nM) EGFR/BTK IC50 (nM) ERBB2/BTK IC50 (nM) ITK/BTK
ibrutinib 0.3 0.1 0 0.2 1 3 10 10 38 78 311
3c 0.1 0.1 1 0.3 5 7 105 33 472 43 607
3h 0.1 0.6 7 0.3 4 28 348 196 2400 295 3613
3e 0.1 0.1 1 0.4 5 3 36 13 169 30 383
3i 0.1 0.8 11 0.4 5 31 417 172 2292 232 3087